HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo [Video]

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center in New York, NY, provides an overview of the Phase III EV-301 trial (NCT03474107) to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer. The study aimed to assess patient experiences of enfortumab vedotin (EV) versus chemotherapy in previously treated advanced urothelial carcinoma using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL). Results showed that patients receiving EV had reduced pain and delayed deterioration in HRQoL compared to those receiving chemotherapy. HRQoL was maintained with EV, with better results reported for some scales, particularly pain. These findings support the safety and efficacy outcomes observed in the EV-301 trial. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.